Using fecal immunochemical tubes for the analysis of the gut microbiome has the potential to improve colorectal cancer screening

被引:0
|
作者
Kertu Liis Krigul
Oliver Aasmets
Kreete Lüll
Tõnis Org
Elin Org
机构
[1] University of Tartu,Institute of Genomics, Estonian Genome Centre
[2] University of Tartu,Department of Biotechnology, Institute of Molecular and Cell Biology
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Colorectal cancer (CRC) is a challenging public health problem which successful treatment depends on the stage at diagnosis. Recently, CRC-specific microbiome signatures have been proposed as a marker for CRC detection. Since many countries have initiated CRC screening programs, it would be useful to analyze the microbiome in the samples collected in fecal immunochemical test (FIT) tubes for fecal occult blood testing. Therefore, we investigated the impact of FIT tubes and stabilization buffer on the microbial community structure evaluated in stool samples from 30 volunteers and compared the detected communities to those of fresh-frozen samples, highlighting previously published cancer-specific communities. Altogether, 214 samples were analyzed by 16S rRNA gene sequencing, including positive and negative controls. Our results indicated that the variation between individuals was greater than the differences introduced by the collection strategy. The vast majority of the genera were stable for up to 7 days. None of the changes observed between fresh-frozen samples and FIT tube specimens were related to previously identified CRC-specific bacteria. Overall, we show that FIT tubes can be used for profiling the microbiota in CRC screening programs. This circumvents the need to collect additional samples and can possibly improve the sensitivity of CRC detection.
引用
下载
收藏
相关论文
共 50 条
  • [1] Using fecal immunochemical tubes for the analysis of the gut microbiome has the potential to improve colorectal cancer screening
    Krigul, Kertu Liis
    Aasmets, Oliver
    Lull, Kreete
    Org, Tonis
    Org, Elin
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [2] Using fecal immmunochemical cartridges for gut microbiome analysis within a colorectal cancer screening program
    Brezina, Stefanie
    Borkovec, Martin
    Baierl, Andreas
    Bastian, Fabienne
    Futschik, Andreas
    Gasche, Nikolaus
    Gruenberger, Thomas
    Hallas, Michael
    Jannsen, Christian
    Leeb, Gernot
    Lutz, Rebecca
    Sladek, Barbara
    Gsur, Andrea
    GUT MICROBES, 2023, 15 (01)
  • [3] Microbiome Profiling from Fecal Immunochemical Test Reveals Microbial Signatures with Potential for Colorectal Cancer Screening
    Khannous-Lleiffe, Olfat
    Willis, Jesse R.
    Saus, Ester
    Moreno, Victor
    Castellvi-Bel, Sergi
    Gabaldon, Toni
    CANCERS, 2023, 15 (01)
  • [4] A colorectal cancer screening outreach using fecal immunochemical tests
    Myslimec, Pauline A.
    Courteau, Steven
    Zhao, Wei K.
    Chung, Elaine H.
    Maurer, Debra R.
    Levin, Theodore R.
    GASTROENTEROLOGY, 2008, 134 (04) : A485 - A486
  • [5] Fecal Immunochemical Tests for Colorectal Cancer Screening
    Daly, Jeanette
    AMERICAN JOURNAL OF NURSING, 2012, 112 (10) : 67 - 69
  • [6] Investigating the Potential of the Faecal Microbiome to Improve Colorectal Cancer Screening
    Young, C.
    Wood, H.
    Balaguer, A. Fuentes
    Benton, S.
    Burtonwood, C.
    Brealey, M.
    Quirke, P.
    JOURNAL OF PATHOLOGY, 2019, 249 : S21 - S21
  • [7] Improve the Colorectal Cancer Diagnosis Using Gut Microbiome Data
    Zhou, Yi-Hui
    Sun, George
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [8] Colorectal Cancer Screening: Fecal immunochemical Test or Sigmoidoscopy?
    Hofmann-Assmus, Marion
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (07): : 626 - 628
  • [9] Optimizing Fecal Immunochemical Testing For Colorectal Cancer Screening
    Schreuders, Eline H.
    Wieten, Els
    Kuipers, Ernst J.
    Spaander, Manon C. W.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (10) : 1498 - 1499
  • [10] Colorectal cancer screening with fecal immunochemical testing in Nigeria
    Chido-Amajuoyi, Onyema Greg
    LANCET GLOBAL HEALTH, 2022, 10 (11): : E1561 - E1561